ATG 101
Alternative Names: ATG-101; ATN-101; Ori-Bs-001; PD-L1/4-1BB bi-specific antibody; YN-051Latest Information Update: 20 Jun 2025
At a glance
- Originator OriCell Therapeutics
- Developer Antengene Corporation
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Programmed cell death-1 ligand-1 inhibitors; Regulatory T-lymphocyte inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 09 Jun 2025 Antengene Biologics Limited terminates a phase-I trial in Non-Hodgkin's lymphoma and Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and Australia (IV) due to the recent changes in the competitor landscape and strategic consideration (NCT04986865)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(In the elderly, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, In adults) in China (IV)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, In adults) in China (IV)